Literature DB >> 15115034

Actor-network theory: a tool to support ethical analysis of commercial genetic testing.

Bryn Williams-Jones1, Janice E Graham.   

Abstract

Social, ethical and policy analysis of the issues arising from gene patenting and commercial genetic testing is enhanced by the application of science and technology studies, and Actor-Network Theory (ANT) in particular. We suggest the potential for transferring ANT's flexible nature to an applied heuristic methodology for gathering empirical information and for analysing the complex networks involved in the development of genetic technologies. Three concepts are explored in this paper--actor-networks, translation, and drift--and applied to the case of Myriad Genetics and their commercial BRACAnalysis genetic susceptibility test for hereditary breast cancer. Treating this test as an active participant in socio-technical networks clarifies the extent to which it interacts with, shapes and is shaped by people, other technologies, and institutions. Such an understanding enables more sophisticated and nuanced technology assessment, academic analysis, as well as public debate about the social, ethical and policy implications of the commercialization of new genetic technologies.

Entities:  

Keywords:  Genetics and Reproduction; Myriad Genetics Inc.

Mesh:

Year:  2003        PMID: 15115034     DOI: 10.1080/1463677032000147225

Source DB:  PubMed          Journal:  New Genet Soc        ISSN: 1463-6778


  7 in total

1.  Structurating Expanded Genetic Carrier Screening: A Longitudinal Analysis of Online News Coverage.

Authors:  Heather E Canary; Yvonne K Clark; Avery Holton
Journal:  J Health Commun       Date:  2018-05-25

2.  Myriad Genetics: In the eye of the policy storm.

Authors:  E Richard Gold; Julia Carbone
Journal:  Genet Med       Date:  2010-04       Impact factor: 8.822

3.  Integrating stakeholder perspectives into the translation of cell-free fetal DNA testing for aneuploidy.

Authors:  Lauren C Sayres; Megan Allyse; Mildred K Cho
Journal:  Genome Med       Date:  2012-06-21       Impact factor: 11.117

Review 4.  Shifting emphasis from pharmacogenomics to theragnostics.

Authors:  Vural Ozdemir; Bryn Williams-Jones; Stephen J Glatt; Ming T Tsuang; James B Lohr; Christopher Reist
Journal:  Nat Biotechnol       Date:  2006-08       Impact factor: 54.908

5.  The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development.

Authors:  Richard Milne
Journal:  New Genet Soc       Date:  2019-07-16

6.  Private and public values of innovation: A patent analysis of synthetic biology.

Authors:  Barbara Ribeiro; Philip Shapira
Journal:  Res Policy       Date:  2020-02

7.  Counseling customers: emerging roles for genetic counselors in the direct-to-consumer genetic testing market.

Authors:  Anna Harris; Susan E Kelly; Sally Wyatt
Journal:  J Genet Couns       Date:  2012-10-25       Impact factor: 2.537

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.